EUROPEAN LUNG CANCER CONFERENCE 2016

Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON Phase Ib trial

Myung-Ju Ahn[1], James C-H Yang[2], Helena Yu[3], Hideo Saka[4], Suresh S Ramalingam[5], Xiangning Huang[6], Liu Yang[7], Mireille Cantarini[8], Andrew Walding[8], Geoffrey R Oxnard[9]

[1]Samsung Medical Center, Seoul, Republic of Korea; [2]National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan; [3]Memorial Sloan Kettering Cancer Center, New York, USA; [4]Nagoya Medical Center, Nagoya, Japan; [5]Emory University, Winship Cancer Institute, Atlanta, USA; [6]AstraZeneca, Cambridge, UK; [7]AstraZeneca, Shanghai, China; [8]AstraZeneca, Macclesfield, UK; [9]Dana-Farber Cancer Institute, Boston, MA, USA

Disclosures

Myung-Ju Ahn – Advisory board: AstraZeneca, Boehringer Ingelheim, Novartis, Eli Lilly, Merck

James C-H Yang – Advisory board: AstraZeneca, Boehringer Ingelheim, Novartis, Eli Lilly, Merck, Bayer, Roche/Genentech, Astellas, MSD, Pfizer, Clovis Oncology, Celgene

Helena Yu – Advisory board: AstraZeneca; research funding: AstraZeneca, Clovis Oncology, Astellas, Incyte and Pfizer

Hideo Saka – Research funding: AstraZeneca

Suresh S Ramalingam – Consultancy: AstraZeneca, Boehringer Ingelheim, Novartis, Eli Lilly, Merck, Genentech, Celgene, Bristol-Myer Squibb

Geoffrey R Oxnard – Honoraria: Chugai; consultancy/advisory board: ARIAD, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Inivata, Sanofi, Sysmex

Mireille Cantarini, Andrew Walding, Xiangning Huang – Employees and shareholders: AstraZeneca

Liu Yang – Employee: AstraZeneca

Introduction

- Osimertinib (AZD9291) is a potent, irreversible EGFR-TKI selective for sensitising EGFRm and T790M resistance mutations[1,2]
- Resistance to EGFR-TKIs can occur through a number of mechanisms. Combinations of molecularly targeted agents may offer clinical benefit by addressing or delaying resistance
- The TATTON multi-arm, open-label, Phase Ib study (NCT02143466) evaluates osimertinib-based combinations in patients with EGFRm advanced NSCLC[3]



1. Cross et al. Cancer Discov 2014;4:1046–1061; 2. Jänne et al. Ann Oncol 2015;26(Suppl 1):i60, LBA3; 3. Oxnard et al. J Clin Oncol 2015;33(Suppl): Abstract 2509
EGFR, epidermal growth factor receptor; EGFRm, EGFR mutation-positive; mAb, monoclonal antibody; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death-ligand 1;TKI, tyrosine kinase inhibitor
Durvalumab (MEDI4736); savolitinib (HMPL-504, volitinib, AZD6094); selumetinib (AZD6244, ARRY-142886)

TATTON: osimertinib + durvalumab arm

Primary objective: safety and tolerability

Treatment location: Asia and USA

Key inclusion criteria: EGFRm NSCLC; adequate performance status and organ function

Key exclusion criteria: History of ILD; live vaccine or immunosuppressants within 1 month

Data cut-off: 13 November 2015

Part A: Dose escalation

Patients who progressed after previous EGFR-TKI therapy; prior anti-PD-L1 or anti-PD-1 treatment excluded



Part B: Dose expansion

Patients with EGFR-TKI treatment-naïve disease

*Part B combination dose chosen based on preliminary signal of clinical efficacy and an acceptable safety and tolerability profile

ILD, interstitial lung disease; IV, intravenous; QD, once daily; Q2W, once every 2 weeks

Baseline characteristics

Characteristic, n	Part A		Part B
	Osimertinib 80 mg QD / durvalumab 3 mg/kg Q2W (N=10)	Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=13)	Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=11)
Gender Male / Female	3 / 7	6 / 7	6 / 5
Age, median (range), years	67 (46–78)	58 (44–73)	57 (46–70)
Treatment location and ethnicity Asia / USA Japanese / Asian / Black / White	 6 / 4 3 / 5 / 1 / 1	 7 / 6 2 / 8 / 1 / 2	 10 / 1 5 / 6 / 0 / 0
Smoker Current / Former / Never / Unknown	0 / 3 / 7 / 0	1 / 1 / 9 / 2	1 / 5 / 5 / 0
Therapy line, median (range)	3.5 (2–10)	3 (2–5)	N/A: all treatment naïve
Immediate prior therapy Gefitinib / Erlotinib / Afatinib / Other	4 / 1 / 3 / 2	2 / 5 / 1 / 5	N/A: all treatment naïve
EGFRm Ex19 del/ L858R / Unknown	6 / 4 / 0	5 / 7 / 1	8 / 2 / 1
T790M status Negative / Positive	7 / 3	7 / 6	11 / 0

Population: safety analysis set; data cut-off: 13 Nov 2015
Ex19 del, exon 19 deletion; N/A, not applicable

Duration of exposure to study drug by cohort*

	Part A				Part B	
	Osimertinib 80 mg QD / durvalumab 3 mg/kg Q2W (N=10)		Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=13)		Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=11)	
	Osimertinib	Durvalumab	Osimertinib	Durvalumab	Osimertinib	Durvalumab
Median duration of exposure, weeks	43.9	13.9	20.1	16.1	14.1	12.3
Duration of exposure range, weeks	3.1–57.6	0.1–47.4	1.3–41.6	0.1–37.3	5.1–21.4	4.4–22.4

- Part A dose 1: 3/10 patients ongoing (2 osimertinib monotherapy, 1 combination)
- Part A dose 2: 5/13 patients ongoing (1 osimertinib monotherapy, 4 combination)
- Part B: 4/11 patients ongoing (2 osimertinib monotherapy, 2 combination)

Population: safety analysis set; data cut-off: 13 Nov 2015
*If a patient was not discontinued, then the cut-off date was used in place of the last dose date

Summary of adverse events

Patients with an AE, n	Part A						Part B‡		
	Osimertinib 80 mg QD / durvalumab 3 mg/kg Q2W (N=10)			Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=13)			Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=11)		
	Any AE	Drug-related*		Any AE	Drug-related*		Any AE	Drug-related*	
		Osi	Durva		Osi	Durva		Osi	Durva
Total AE	10	10	8	13	9	7	10	8	10
AE Grade ≥3	6	3	2	4	2	2	6	6	5
AE leading to osimertinib discontinuation†	2	1	N/A	2	2	N/A	5	5	N/A
AE leading to durvalumab discontinuation†	4	N/A	3	4	N/A	4	5	N/A	5
AE leading to death	0	0	0	1	0	0	0	0	0
SAE	6	2	4	3	1	1	4	4	4

Population: safety analysis set; data cut-off: 13 Nov 2015

*Possibly-related, as assessed by the investigator; †Patients could discontinue either one or both agents dependent on causality assessment; ‡Part B combination dose chosen based on preliminary signal of clinical efficacy and an acceptable safety and tolerability profile

AE, adverse event; Durva, durvalumab; N/A, not applicable; Osi, osimertinib; SAE, serious adverse event

All-causality adverse events

AE by preferred term, occurring in >3 patients at any dose, n	Part A				Part B	
	Osimertinib 80 mg QD / durvalumab 3 mg/kg Q2W (N=10)		Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=13)		Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=11)	
	Any grade	Grade ≥3	Any grade	Grade ≥3	Any grade	Grade ≥3
Rash (grouped terms)	5	1	6	0	7	0
ILD (grouped terms)	2	1	4	1	7*	3
Diarrhoea	3	0	3	0	5	0
Pyrexia	2	0	2	0	4	0
Stomatitis	1	0	1	0	4	0
Nausea	3	0	5	0	3	0
Anaemia	4	0	4	1	1	0
Vomiting	7	1	2	0	0	0
Decreased appetite	3	1	4	0	1	0

*One patient reported ILD following 13 Nov 2015 data cut-off
Population: safety analysis set; data cut-off: 13 Nov 2015

Time to onset and frequency of interstitial lung disease

- Time to ILD onset in TATTON (n=13):
  - Mean 80 days
  - Median 69 days

Part A	6/23 (26%)
Dose 1: Osimertinib 80 mg QD / durvalumab 3 mg/kg Q2W	2/10 (20%)
Dose 2: Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W	4/13 (31%)
Part B: Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W	7*/11 (64%)
Part A and Part B	13/34 (38%; 95% CI 18, 52)†

†5 events were Grade 3/4 and there were no fatalities; most cases were managed using steroids

Osimertinib monotherapy (entire clinical programme, Phase I and II)	35/1207 (2.9%)
Durvalumab monotherapy	23/1149 (2.0%)

*One patient reported ILD following 13 Nov 2015 data cut-off
TATTON Population: safety analysis set; data cut-off: 13 Nov 2015

Tumour response



Population: evaluable for response set; data cut-off: 13 Nov 2015
ORR, objective response rate

Response rate and duration of response

	Part A		Part B
	Osimertinib 80 mg QD / durvalumab 3 mg/kg Q2W (N=10)	Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=13)	Osimertinib 80 mg QD / durvalumab 10 mg/kg Q2W (N=10)
Confirmed responses, n (%; 95% CI)	4 (40%; 12, 74)	5 (39%; 14, 68)	7 (70%; 35, 93)
Patients with T790M positive NSCLC	6/9 (67%; 30, 93)		N/A
Patients with T790M negative NSCLC	3/14 (21%; 5, 51)		N/A



Population: evaluable for response set; data cut-off: 13 Nov 2015
x = end of response. Arrow represents censored observations at the data cut-off

Conclusions

- An increase in ILD was reported with the combination of osimertinib and durvalumab compared to what would be expected with either drug alone. Etiology is being investigated
- ILD (grouped terms) was reported in 38% (13/34) of patients
  - Five events at Grade 3/4 and no fatalities
  - Osimertinib monotherapy: ILD (grouped terms) reported in 2.9% (35/1207) of patients
  - Durvalumab monotherapy: ILD (grouped terms) reported in 2.0% (23/1149) of patients
- In patients with prior EGFR-TKI therapy, investigator-assessed ORR was 67% (6/9) and 21% (3/14) in those with T790M positive and T790M negative NSCLC, respectively, and 70% (7/10) in EGFRm treatment-naïve patients
- Based on the observed safety data, the recruitment into the osimertinib + durvalumab treatment arm of TATTON is currently on hold
  - TATTON continues to enrol expansion cohorts of MET and MEK inhibitor combinations

Acknowledgements

- Thank you to all the patients and families
- Thank you to the staff and investigators at all 21 sites:
  - Japan: Dr Koichi Goto, Dr Yuichiro Ohe, Dr Hideo Saka, Dr Takayasu Kurata, Dr. Toyoaki Hida, Dr Tomonori Hirashima
  - South Korea: Prof Myung-Ju Ahn, Prof Sang-We Kim, Prof Jong Seok Lee, Prof Byoung Chul Cho, Prof Ji-Youn Han
  - Taiwan: Dr James Chih-Hsin Yang, Dr Chun-Ming Tsai, Dr Wu-Chou Su
  - United States of America: Dr Geoffrey Oxnard, Dr Helena Yu, Dr Suresh Ramalingam, Dr Leora Horn, Dr Geoffrey Oxnard, Dr Kathryn Gold

This study was sponsored by AstraZeneca, ClinicalTrials.gov identifier NCT02143466
Editorial assistance was provided by Natasha Cary, BSc of iMed Comms an Ashfield Company, and funded by AstraZeneca